A Phase 4 interventional study of 6-Gingerol and Triamcinolone Acetonide 0.1% Oromucosal Paste in Oral Lichen Planus, sponsored by Ain Shams University. Not yet recruiting. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-05-31.
Sponsored by Ain Shams University · Phase 4, Interventional, and Treatment
Among 10 studies in Lichen Planus, Oral by Ain Shams University — 3 open to participants now, 4 under way, none of them phase 3. Lichen Planus, Oral · Ain Shams University.
Among the 10 studies in Lichen Planus, Oral by Ain Shams University, this one is the only one that started in 2023, is one of 7 in phase 4, and was the 4th registered.
142 studies on the registry are indexed under Lichen Planus, Oral; 27 are open to participants now.
Browse Lichen Planus, Oral studies →3 of the 10 studies in Lichen Planus, Oral by Ain Shams University are open now. Recruiting first, the newest first:
Ain Shams University
Ages 30–75
Ain Shams University
Ages 40–75 · Healthy volunteers
Of the 14 Lichen Planus, Oral studies recruiting now, 10 (71%) set no upper age limit and 2 (14%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 40 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is below the median of 39 across 101 interventional studies indexed under Lichen Planus, Oral.
Median enrollment 29 across the 8 interventional studies, 70 across the 2 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ain Shams University is the lead sponsor of 1,953 studies on the registry; 430 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
2 of the studies in Lichen Planus, Oral by Ain Shams University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07318922Ain Shams UniversityEvaluation of Artificial Intelligence in Diagnosis and Risk Assessment of Oral Potentially Malignant Disorders | 2026-11-22 |
| NCT07846891Ain Shams UniversityLow Level Laser Therapy With Injectable Platelet Rich Fibrin in Management of Oral Lichen Planus | 2027-04-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Lichen Planus, Oral by Ain Shams University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group I Will include 14 patients receiving topical ginger extract 1% four times per day (after every meal and before going to bed) for eight weeks (Zakaria et al., 2020).
Drug: 6-Gingerol
Group II Will include 14 patients receiving topical steroid (triamcinolone acetonide 0.1%) four times per day for eight weeks (Laeijendecker et al., 2006) In the fourth and eighth weeks, topical anti-fungal will be applied by a third-party medical personnel to avoid 2ry candidiasis for this group.
Drug: Triamcinolone Acetonide 0.1% Oromucosal Paste
6-gingerol gel will be applied locally to the participants suffering from oral lichen planus
Triamcinolone Acetonide 0.1% gel will be applied locally to the participants suffering from oral lichen planus
Efficacy of Ginger Muco-bioadhesive Gel in Management of Oral Lichen Planus
Analysis of 6-Gingerol gel in Management of Oral Lichen Plauns using Immunohistochemistry
Time frame: Baseline
No study locations are listed for this record.
Start is estimated for Aug 2023; primary completion for Jun 2025, 22 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triamcinolone Acetonide